drugset
drugset / Trial / NCT03383055

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

NCT03383055 ↗

Phase 1 Completed 28 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.

Timeline

Start
2018-11-16
Primary completion
2021-07-10
Completion
2021-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Vaccine — —
Background TDap Unknown — —

Indications

plasma cell myeloma